Orchestra BioMed Holdings, Inc.

Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) is a biomedical innovation company focused on developing and commercializing implantable medical device technologies, with its lead program, BackBeat Medical, targeting hypertension through cardiac neuromodulation. The company operates in the medical devices and life sciences sector and entered the public markets through a SPAC transaction. On March 31, 2022, Orchestra BioMed filed an amended annual report on Form 10-K/A with the SEC, reflecting restated or supplemented disclosures for the relevant fiscal period. The company's development-stage profile and SPAC-merger history place it among closely watched names in the healthcare-focused blank-check space. For complete filing history, transaction details, and real-time SPAC analytics on OBIO and thousands of other SPAC-linked companies, sign up for full data access at SpacDesk.